Centiloid recommendations for clinical context‐of‐use from the AMYPAD consortium
Alzheimer's & Dementia · 2024-12 · 20 (12) · 9037-9048
DOI: 10.1002/alz.14336 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Alzheimer's & Dementia, online erschienen am 20.11.2024. Verfasst von Lyduine E Collij und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology & Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Positron-Emission Tomography. Die Arbeit wurde bisher 134-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, Innovative Medicines Initiative, European Union's Horizon 2020.
Abstract (Originalsprache)
Amyloid‐PET quantification through the tracer‐independent Centiloid (CL) scale has emerged as an essential tool for the accurate measurement of amyloid‐β (Aβ) pathology in Alzheimer's disease (AD) patients. The AMYPAD consortium set out to integrate existing literature and recent work from the consortium to provide clinical context‐of‐use recommendations for the CL scale. Compared to histopathology, visual reads, and cerebrospinal fluid, CL quantification accurately reflects the amount of AD pathology. With high certainty, a CL value below 10 excludes the presence of Aβ pathology, while a value above 30 corresponds well with pathological amounts. Values falling in between these two cutoffs (“intermediate range”) are related to an increased risk of disease progression. Together, CL quantification is a valuable adjunct to visual assessments of amyloid‐PET images. An abnormal amyloid biomarker assessment is a key criterion to determine eligibility for anti‐amyloid disease‐modifying therapies, and amyloid‐PET quantification can add further value by precisely monitoring amyloid clearance, and hence guiding patient management decisions. Highlights Centiloid (CL) quantification robustly reflects of the amount of Aβ pathology. CL < 10/CL > 30 reflects Aβ‐negativity/positivity thresholds with high certainty. CL quantification is a valuable adjunct to visual assessments of amyloid‐PET. CL quantification can support trial design and treatment management. CL quantification could support the identification of early or emerging Aβ pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology & Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
- Brain Imaging, Amsterdam Neuroscience, Amsterdam, The Netherlands.
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Malmö, Sweden.
- GE Healthcare, Chalfont St Giles, Buckinghamshire, UK.
- Centre for Medical Image Computing, University College London, London, UK.
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, California, USA.
ORCID-Profile: Lyduine E Collij, Ariane Bollack, Renaud La Joie, Mahnaz Shekari, Norman Koglin, David Valléz Garciá, Valentina Garibotto, Andrew W Stephens, Frederik Barkhof, Juan Domingo Gispert
Förderung
- NIA NIH HHS
- Innovative Medicines Initiative
- European Union's Horizon 2020
- Innovative Medicines Initiative 2 Joint Undertaking
- EFPIA
- European Federation of Pharmaceutical Industries and Associations
Zitieren
APA
Collij, L. E., Bollack, A., La Joie, R., Shekari, M., Bullich, S., Roé-Vellvé, N., Koglin, N., Jovalekic, A., Garciá, D. V., Drzezga, A., Garibotto, V., Stephens, A. W., Battle, M., Buckley, C., Barkhof, F., Farrar, G., Gispert, J. D., & AMYPAD consortium (2024). Centiloid recommendations for clinical context‐of‐use from the AMYPAD consortium. Alzheimer's & Dementia, 20(12), 9037-9048. https://doi.org/10.1002/alz.14336
Vancouver
Collij LE, Bollack A, La Joie R, Shekari M, Bullich S, Roé-Vellvé N, et al. Centiloid recommendations for clinical context‐of‐use from the AMYPAD consortium. Alzheimer's & Dementia. 2024;20(12):9037-9048. doi:10.1002/alz.14336
BibTeX
@article{Collij2024,
author = {Collij, Lyduine E and Bollack, Ariane and La Joie, Renaud and Shekari, Mahnaz and Bullich, Santiago and Roé-Vellvé, Núria and Koglin, Norman and Jovalekic, Aleksandar and Garciá, David Valléz and Drzezga, Alexander and Garibotto, Valentina and Stephens, Andrew W and Battle, Mark and Buckley, Christopher and Barkhof, Frederik and Farrar, Gill and Gispert, Juan Domingo and AMYPAD consortium, AMYPAD consortium},
title = {Centiloid recommendations for clinical context‐of‐use from the AMYPAD consortium},
journal = {Alzheimer's & Dementia},
year = {2024},
volume = {20},
number = {12},
pages = {9037--9048},
doi = {10.1002/alz.14336}
}
EUVIMED